Alpha Tau Medical Ltd

NASDAQ DRTS

Download Data

Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio 2 year CAGR for the year ending December 31, 2023: 31.44%

Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio 2 year CAGR is 31.44% for the year ending December 31, 2023, a 667.13% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio for the year ending December 31, 2022 was 23.55, a 267.32% change year over year.
  • Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio for the year ending December 31, 2021 was 6.41, a -70.50% change year over year.
  • Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio for the year ending December 31, 2020 was 21.73, a 2.92% change year over year.
  • Alpha Tau Medical Ltd Working Capital to Current Liabilities Ratio for the year ending December 31, 2019 was 21.11.
NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO Mr. Uzi Sofer
IPO Date March 8, 2021
Location Israel
Headquarters 5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees 121
Sector Healthcare
Industry Biotechnology
Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Similar companies

TNYA

Tenaya Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email